Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis

BACKGROUND: In ulcerative colitis (UC), the molecular mechanisms that drive disease development and patient response to therapy are not well understood. A significant proportion of patients with UC fail to respond adequately to biologic therapy. Therefore, there is an unmet need for biomarkers that...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Amrinder, Fenton, Christopher G., Anderssen, Endre, Paulssen, Ruth H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167201/
https://www.ncbi.nlm.nih.gov/pubmed/35543875
http://dx.doi.org/10.1007/s00384-022-04176-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167201/
https://www.ncbi.nlm.nih.gov/pubmed/35543875
http://dx.doi.org/10.1007/s00384-022-04176-w

Ejemplares similares